AEZS Aeterna Zentaris Inc

Shares of companies focused on cancer treatment have been volatile this month following the much-anticipated annual meeting of the American Society for Clinical Oncology, also known as ASCO. While positive data initially drove shares of several biotech firms higher, a barrage of profit taking followed. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides stock analysis on Vical, Inc. (NASDAQ: VICL) and AEterna Zentaris Inc. (NASDAQ: AEZS). Access to the full company reports can be found at:

www.bedfordreport.com/VICL

www.bedfordreport.com/AEZS

Cancer, projected to become the leading cause of death worldwide this year by the World Health Organisation, has emerged as the costliest disease, costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for investors.

It is also an inherently risky sector. Earlier this year Reuters published research from BioMed Tracker and BIO, which claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards, recommending that sponsors generally be required to conduct randomized trials rather than single-arm studies, and that there be more extensive postmarketing studies to confirm clinical benefit.

The Bedford Report releases investment research on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

AEterna Zentaris Inc. is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. During the most recent quarter, the company reached an agreement with Yakult Honsha Co. Ltd. for the development, manufacture and commercialization of AEterna Zentaris' lead anticancer compound, perifosine, in Japan.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: The Bedford Report Email Contact